George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Most other biotech stocks have had a good bounce and recovery in the last few months (especially in the US).
About time we see that as well. This stock has fallen too far imo.
I think the penny is starting to drop. The only reason I can come up with after the funding needed runs even with millions in the bank, was to suppress the SP for whatever reason. Everything that has happened since doesn't change my mind. Quick to runs some hypothetical future need for funding but silence on some good (though not world changing) sales news.
Sales of our recently launched ALKINDI SPRINKLE® remain strong, with 293% year-over-year revenue growth, and feedback from the patient and physician communities continues to be overwhelmingly positive.
Continued growth in ALKINDI SPRINKLE®. ALKINDI SPRINKLE sales grew 293% over the second quarter of 2021 and 34% over the first quarter of 2022, demonstrating a strong desire for the low-dose treatment options that ALKINDI SPRINKLE offers.
man alive but you'd think they'd be at least tweeting something to at least suggest the bigger world wide sales picture, from this news!
https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-reports-second-quarter-2022-financial
They should still own some Eton shares too.
Efmody stuff the price, when Scotland didn't take it up for the NHS but if they re-submit on the wave of Alkindi news then, if it got passed this time could easily see old numbers, which mean multibagging.
need to implicate world sales of Alkindi and then geta premium fund sorted... then approach Scotland again to nail the miserable historical aberration.